{"id":542210,"date":"2021-05-07T14:06:01","date_gmt":"2021-05-07T14:06:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=542210"},"modified":"2021-05-07T14:06:01","modified_gmt":"2021-05-07T14:06:01","slug":"adult-tcell-leukemialymphoma-atll-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/adult-tcell-leukemialymphoma-atll-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-delveinsight_542210.html","title":{"rendered":"Adult T-cell LeukemiaLymphoma (ATLL) Market Analysis, Market Size, Epidemiology, Leading Companies And Competitive Analysis | Delveinsight"},"content":{"rendered":"
\"Adult<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201cAdult T-cell leukemia-lymphoma (ATLL) \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u2033 report deliver an in-depth understanding of the Adult T-cell leukemia-lymphoma (ATLL), historical and forecasted epidemiology as well as the Adult T-cell leukemia-lymphoma (ATLL) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on “Adult T-cell leukemia-lymphoma (ATLL) – Market Insights, Epidemiology, and Market Forecast-2030<\/a>.<\/strong><\/p>\n

DelveInsight’s “Adult T-cell leukemia-lymphoma (ATLL) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>″ report deliver an in-depth understanding of the Adult T-cell leukemia-lymphoma (ATLL), historical and forecasted epidemiology as well as the Adult T-cell leukemia-lymphoma (ATLL) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. \n

    The age-standardized incidence of ATLL in non-endemic areas in Japan and in the US significantly increased during the period (1993 to 2006 for Japan) and (1993 to 2008) with an annual percent change of 95% <\/p>\n<\/li>\n

  2. \n

    The age-standardized incidence of ATLL in Japan-Honshu was +4.6% and in the United States was +6.2% <\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

    1. Adult T-cell leukemia-lymphoma (ATLL) market report covers a descriptive overview and comprehensive insight of the Adult T-cell leukemia-lymphoma (ATLL) epidemiology and Adult T-cell leukemia-lymphoma (ATLL) market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

    2. Adult T-cell leukemia-lymphoma (ATLL) market report provides insights on the current and emerging therapies.<\/p>\n

    3. Adult T-cell leukemia-lymphoma (ATLL) market report provides a global historical and forecasted market covering drug outreach in 7 MM.<\/p>\n

    4. Adult T-cell leukemia-lymphoma (ATLL) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Adult T-cell leukemia-lymphoma (ATLL) market.<\/p>\n

    Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/adult-t-cell-leukemia-lymphoma-market<\/span><\/a><\/strong><\/p>\n

    Adult T-cell leukemia-lymphoma (ATLL): Overview<\/strong><\/p>\n

    Adult T-cell leukemia\/lymphoma (ATLL) is a rare and often aggressive (fast-growing) T-cell lymphoma that can be found in the blood (leukemia), lymph nodes (lymphoma), skin, or multiple areas of the body.ATLL has been linked to infection with the human T-cell lymphotropic virus type 1 (HTLV-1); however, less than five percent of individuals with HTLV-1 will develop ATLL. The HTLV-1 virus is most common in parts of Japan, the Caribbean, and some areas of South and Central America and Africa. Currently, physicians have no way of predicting which infected patients will develop ATLL.<\/p>\n

    The key players involved in the Adult T-cell leukemia-lymphoma (ATLL) market:<\/strong><\/a><\/p>\n

    Marketed Therapies<\/strong><\/p>\n

      \n
    1. \n

      Kyowa Hakko Kirin<\/p>\n<\/li>\n

    2. \n

      Celgene Corporation<\/p>\n<\/li>\n<\/ol>\n

      Emerging Therapies<\/strong><\/p>\n

        \n
      1. \n

        Seattle Genetics <\/p>\n<\/li>\n

      2. \n

         HUYA Bioscience International <\/p>\n<\/li>\n<\/ol>\n

        The launch of the emerging therapies is expected to significantly impact the Adult T-cell LeukemiaLymphoma (ATLL) treatment scenario in the upcoming years:-<\/strong><\/p>\n

        Drugs covered<\/strong><\/p>\n

        Marketed Therapies<\/strong><\/p>\n

          \n
        1. \n

          POTELIGEO<\/p>\n<\/li>\n

        2. \n

          Revlimid<\/p>\n<\/li>\n<\/ol>\n

          Emerging Therapies<\/strong><\/p>\n

            \n
          1. \n

            Brentuximab vedotin<\/p>\n<\/li>\n

          2. \n

            HBI-8000<\/p>\n<\/li>\n<\/ol>\n

            Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/adult-t-cell-leukemia-lymphoma-market<\/span><\/a><\/strong><\/strong><\/p>\n

            Table of Contents<\/strong><\/p>\n

            1. Report Introduction<\/p>\n

            2. Executive Summary<\/p>\n

            3. SWOT analysis<\/p>\n

            4. Adult T-cell leukemia-lymphoma (ATLL) Patient Share (%) Overview at a Glance<\/p>\n

            5. Adult T-cell leukemia-lymphoma (ATLL) Market Overview at a Glance<\/p>\n

            6. Adult T-cell leukemia-lymphoma (ATLL) Disease Background and Overview<\/p>\n

            7. Adult T-cell leukemia-lymphoma (ATLL) Epidemiology and Patient Population<\/p>\n

            8. Country-Specific Patient Population of Adult T-cell leukemia-lymphoma (ATLL)<\/p>\n

            9. Adult T-cell leukemia-lymphoma (ATLL) Current Treatment and Medical Practices<\/p>\n

            10. Unmet Needs<\/p>\n

            11. Adult T-cell leukemia-lymphoma (ATLL) Emerging Therapies<\/p>\n

            12. Adult T-cell leukemia-lymphoma (ATLL) Market Outlook<\/p>\n

            13. Country-Wise Adult T-cell leukemia-lymphoma (ATLL) Market Analysis (2017–2030)<\/p>\n

            14. Market Access and Reimbursement of Therapies<\/p>\n

            15. Market drivers<\/p>\n

            16. Market barriers<\/p>\n

            17. Appendix<\/p>\n

            18. Adult T-cell leukemia-lymphoma (ATLL) Report Methodology<\/p>\n

            19. DelveInsight Capabilities<\/p>\n

            20. Disclaimer<\/p>\n

            21. About DelveInsight<\/p>\n

            Related Reports:<\/strong><\/p>\n

            Adult T-Cell Leukemia-Lymphoma – Pipeline Insights, 2021<\/strong><\/p>\n

            “Adult T-cell leukemia-lymphoma (ATLL) Pipeline Insight, 2020” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Adult T-cell leukemia-lymphoma (ATLL) market. A detailed picture of the Adult T-cell leukemia-lymphoma (ATLL) pipeline landscape is provided, which includes the disease overview and Adult T-cell leukemia-lymphoma (ATLL) treatment guidelines.<\/p>\n

            Adult T-Cell Leukemia-Lymphoma – Epidemiology Forecast to 2030<\/strong><\/p>\n

            DelveInsight’s ‘Adult T-cell LeukemiaLymphoma (ATLL) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Adult T-cell LeukemiaLymphoma (ATLL) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

            Media Contact<\/span>
            Company Name:<\/strong>             DelveInsight Business Research LLP<\/a>
            Contact Person:<\/strong> Kritika Rehani
            Email:<\/strong>             Send Email<\/a>
            Phone:<\/strong> 9193216187
            Address:<\/strong>304 S. Jones Blvd #2432
            City:<\/strong> Las Vegas
            State:<\/strong> Nevada
            Country:<\/strong> United States
            Website:<\/strong>             https:\/\/www.delveinsight.com\/<\/a><\/p>\n

            <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

            DelveInsight Business Research LLP DelveInsight\u2019s \u201cAdult T-cell leukemia-lymphoma (ATLL) \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u2033 report deliver an in-depth understanding of the Adult T-cell leukemia-lymphoma (ATLL), historical and forecasted epidemiology as well as the Adult T-cell leukemia-lymphoma (ATLL) market … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-542210","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542210","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=542210"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542210\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=542210"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=542210"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=542210"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}